Welcome to our dedicated page for Aspira Women`s Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women`s Health stock.
Aspira Women’s Health Inc. (formerly trading on Nasdaq under AWH) generates frequent news as a bio-analytical based women’s health company focused on noninvasive, AI-powered diagnostic tests for gynecologic diseases. Its updates often center on the commercial performance of OvaSuiteSM, which includes the OvaWatch® and Ova1Plus® blood tests for assessing ovarian cancer risk in women with adnexal masses.
News coverage commonly includes quarterly and annual financial results, where Aspira reports product revenue, OvaSuite test volumes, gross profit, operating expenses, and net loss. These releases may also describe changes in sales productivity, cost controls, and balance sheet items such as cash, liabilities, and stockholders’ deficit.
Another key category of Aspira news involves its research and development pipeline, particularly the ENDOinform™ program. The company has issued multiple announcements about its milestone-based award from the ARPA-H Sprint for Women’s Health initiative, detailing milestone achievements, associated cash payments, and progress toward a non-invasive, AI-enabled blood test for endometriosis using protein and microRNA biomarkers plus patient data.
Corporate governance and capital markets developments are also frequent topics. Aspira has reported Board and executive appointments, equity and convertible note financings, and changes in its listing status, including a delisting notification from Nasdaq and subsequent trading on OTC markets under related symbols. Together, these news items provide investors and observers with insight into Aspira’s diagnostic portfolio, pipeline evolution, financial condition, and corporate actions.
For anyone tracking AWH-related news, this page aggregates press releases and other coverage related to ovarian cancer risk assessment tests, endometriosis diagnostics development, ARPA-H milestones, financial updates, and boardroom or listing changes.
Aspira Women’s Health, Inc. (AWH) is set to report its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020, after market close. An investor conference call will follow at 4:30 p.m. ET. The company focuses on innovative testing solutions for women's health, particularly in ovarian cancer risk assessment and pelvic disease management. Aspira is positioned to address ethnic disparities in health outcomes through its product portfolio, including OVA1 plus and ASPIRA GenetiX testing.
Aspira Women’s Health Inc. (Nasdaq: AWH) announces a significant expansion of network access for its OVA1® and ASPIRA GenetiX® testing, now serving approximately 3.3 million members of Anthem BlueCross BlueShield of Georgia. This partnership allows Aspira to reach nearly 30% of Georgia’s population, enhancing access to crucial ovarian cancer risk assessment tools. The company is committed to addressing ethnic disparities in ovarian cancer, focusing on delivering innovative testing solutions for women across various demographics.
Aspira Women’s Health, Inc. (Nasdaq: AWH) has been invited to present at the MicroCap Rodeo Best Ideas Bowl, occurring virtually from October 13-16, 2020. The company’s presentation is scheduled for October 14 from 11:30-11:55 am EST, and will be available for live streaming and replay. Aspira focuses on innovative testing solutions for women’s health, specifically addressing ovarian cancer risk assessment and pelvic diseases. Interested parties can register for the webcast or one-on-one meetings via the provided links.
Aspira Women’s Health (Nasdaq: AWH) will host a key opinion leader (KOL) call on September 25, 2020, at 12:00 PM ET, to discuss ovarian cancer diagnostics and their innovation pipeline. KOLs Dr. Christopher Bryant and Dr. Gerard P. Reilly will present insights on current diagnostics, treatment options, and AWH’s clinical studies. The management team will also share details on their rebranding initiatives and products like OVA1 plus. Interested parties can register.